PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A. (PHXM) Revenue
Annual & quarterly revenue history · segment & region breakdown
PHXM · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsPHAXIAM Therapeutics S.A. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2023.
Revenue trend
2023 – 2010 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | -$0.01B | -100.00% |
| 2019-12-31 | $0.01B | +$0.01B | — |
| 2018-12-31 | $0.00B | -$0.00B | -100.00% |
| 2017-12-31 | $0.00B | -$0.02B | -82.94% |
| 2016-12-31 | $0.02B | +$0.01B | +82.99% |
| 2015-12-31 | $0.01B | +$0.01B | +146.65% |
| 2014-12-31 | $0.00B | +$0.00B | +142.45% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income PHAXIAM Therapeutics S.A. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
PHAXIAM Therapeutics S.A. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in EUR.
Data sourced from PHAXIAM Therapeutics S.A.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
PHXM revenue · 4 questionsPHXM's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2023.
▸ Source: FMP · PHAXIAM Therapeutics S.A. SEC filings · GAAP · PHAXIAM Therapeutics S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026